Introduction
Transfer of therapeutically beneficial genes to the central nervous system is an experimental concept that potentially can be applied to a variety of disorders, including neurodegenerative diseases. 1 However, to achieve successful treatment of diseases characterized by a chronic and progressive course, for instance Parkinson's disease (PD), sustained administration of the therapeutic molecule is a requirement.
Ex vivo, or indirect, gene transfer to the CNS is attractive from a safety point of view, however, the use of current vector systems are limited by down-regulation of transgene expression following cell engraftment. [2] [3] [4] Current approaches to ex vivo gene transfer frequently employ retroviral vectors directing transgene expression typically from the internal LTR promoter 3 or the heterologous CMV promoter, 2 however, transgene down-regu- lation has occurred independently of promoter. Consequently, exploring alternative promoters and vector types may efficiently address the expression stability issue. The human ubiquitin C (UbC) promoter directs high ubiquitous expression of transgenes in transgenic mice 5 and has shown to be a strong constitutive promoter in heterologous expression systems. 6 In the present study, the ability of the UbC promoter to direct sustained in vitro, and in vivo expression in rat brain by ex vivo gene transfer was evaluated and compared with the CMV promoter. In a parallel strategy we combined the elements of the tetracycline responsive expression (Tet) system 7 in a single vector, to assess the possibility that an inducible promoter is less prone to in vivo down-regulation. The Tet system might be less prone to transcriptional down-regulation as it has been shown that only a few copies of the transactivator protein is sufficient to obtain full induction. 8, 9 Hence, near complete silencing of the CMV promoter that drives transactivator expression could still promote stable activation of the inducible promoter. Finally, we exploited the inherent qualities of lenti viral (LV) vectors for stable and regulated transgene expression. LV vectors have been shown to be very efficient vehicles for directing high and sustained in vivo transgene expression in the CNS. 10 The Tet system has been used successfully in other viral vector systems to control transgene expression 11, 12 and we investigated if this could also be applied to the LV system. We also employed recent developments in the Tet system to demonstrate that very closely regulated transgene expression could be obtained.
Results

Influence of promoter on expression stability: comparison of CMV and UbC promoters
The possibility that a strong house-keeping promoter would better maintain expression stability in vitro and in vivo was tested by comparing the human ubiquitin (UbC) promoter to the commonly used, virus-derived CMV promoter (Figure 1a) .
GDNF protein levels in randomly picked clones of CHO cells stably transfected with pUbi1z-GDNF and pCMVz-GDNF (n = 15/group) showed comparable expression levels from the UbC promoter and the CMV promoter ( Figure 1b) . To compare the long-term in vitro expression stability between the two promoters stable clones of an immortalized, rat neuroprogenitor cell line, HiB5 expressing enhanced green fluorescent protein (EGFP) reporter gene were generated. In two clones monitored over a 145-day period, the expression from both the human UbC-and the CMV promoter was stable (Figure 1c ). Long-term sustained in vitro expression from UbC and CMV promoters was also demonstrated in CHO cells (data not shown). These results demonstrate that for transgene expression the UbC promoter is comparable to the CMV promoter in terms of strength and durability in vitro. For in vivo studying transgene expression stability, HiB5 cells represent a suitable platform cell line. Previous in vivo studies have shown that the immortalized HiB5 cell line survive grafting very well, remain stable for at least 6 months and become structurally integrated within an area surrounding the implantation site. [13] [14] [15] The in vivo expression stability of UbC and CMV constitutive promoters was compared by transplanting HiB5 cells stably expressing EGFP from the UbC promoter or the CMV promoter to the striatum. Expression of EGFP from both promoters was significantly down-regulated over 21 days ( Figure 2 ) and no difference in expression stability was seen between cells expressing EGFP under the CMV or UbC promoters, respectively (data from CMV-EGFP not shown). At 3 days after transplantation, many EGFP+ cells were seen at the transplantation site (Figure 2a, d) . The cells almost exclusively displayed an immature morphology devoid of neurites. At 7 days after grafting, much fewer EGFP+ cells were seen and the majority required amplification with a EGFP antibody to be visualized (Figure 2b and e). The majority of EGFP+ cells at this time-point displayed a differentiated astroglial or neuronal morphology (Figure 2h and i). At 21 days, only single EGFP+ cells were found close to the needle tract (Figure 2c and f) .
Since the UbC and the CMV promoter showed similar in vitro and in vivo expression stability, we exclusively employed the UbC promoter for additional in vivo experiments. We measured the amount of GDNF released from grafted HiB5 cells stably expressing GDNF from the UbC construct. Measurement of GDNF tissue levels in animals implanted with HiB5-GDNF clone 7 showed significantly higher nigral GDNF levels at 3 days after implantation compared with HiB5-EGFP implanted animals (0.36 ± 0.05 ng/sample versus 0.12 ± 0.01 ng/sample, respect- ively; P Ͻ 0.01, unpaired t test), while at 21 days after implantation, the GDNF levels were similar to endogenous levels (0.15 ± 0.02 ng/sample). To test if the expression levels, despite down-regulation, would produce sufficient amount of GDNF to provide neuroprotection of lesioned nigral dopamine neurons, HiB5-GDNF clone 7 was implanted above the substantia nigra 4 days before a terminal 20 g 6-OHDA lesion. At 3 weeks after lesion, no significant protection of retrogradely labeled neurons was observed in animals engrafted with GDNF releasing cells compared with animals engrafted with HiB5-EGFP control cells (35 ± 4% and 28 ± 3% of the intact control side, respectively; P > 0.05, unpaired t test). Similar results were obtained with HiB5-GDNF clone 14 (data not shown).
Gene Therapy
Evaluation of tetracycline-induced expression system for enhanced expression stability To test whether expression stability could be improved by inserting the transgene under control of the Tet expression system, a single vector, pJJ/GTE, was generated by combining the Tet-on elements (Figure 3a) . In this construct GDNF and EGFP is co-expressed from a regulatable bi-directional minimal promoter. The transactivator, rtTA, is constitutively expressed from a CMV promoter on a separate expression cassette residing on the same plasmid. Reconstructing the Tet-on two-vector system to a single construct will allow the establishment of inducible clones in one round of transfection.
pJJ/GTE was transfected into HiB5 cells and stable clones were assayed for GDNF levels by ELISA and flu- orescence intensity by a reader or by FACS analysis. Addition of 1 g/ml of doxycyclin to the culture medium resulted in a two-to 25-fold increase in EGFP fluorescence intensity. At full induction the GDNF expression or fluorescence levels were comparable to that seen with the constitutive promoters UbC and CMV ( Figure 3b ). In addition, all clones showed clear doxycyclin dose-dependent induction kinetics and close correlation between fluorescence and GDNF expression, as illustrated for clone z9 (Figure 3c ). In vitro expression reached a stable level 4 days after doxycyclin addition or removal (data not shown). All clones isolated and tested showed varying, basal expression in the absence of doxycyclin. Different factors, beside the effect of the integration site, that could affect the level of basal expression include: (1) low affinity binding of rtTA to the response element in the absence of doxycyclin; (2) enhancer elements in the CMV promoter (driving rtTA expression) promoting the activity of the minimal promoter contained in the TRE, alternatively, read through from the same promoter; or (3) basal activity of the minimal promoter. To investigate the first possibility, a translational stop signal was introduced in the rtTA coding sequence, generating pJJ/GTE stop . The CMV promoter and part of the rtTA coding sequence was deleted, generating pJJ/GTE dCR, to investigate if the CMV promoter contributed to the basal expression level. Basal and induced expression levels were measured in stable polyclonal HiB5 cultures -each represented by between three and 400 clones -transfected with the native pJJ/GTE or the mutant constructs. While transgene expression could only be induced in the native construct containing an intact rtTA transcription unit, basal expression levels were similar for all constructs and were not affected by the introduced mutations ( Figure 4a ). Basal expression of the minimal promoter in the absence of inducer or potential cis-acting elements was further shown by the presence of EGFP expressing cells 2 days after transfection of HiB5 cells with a DNA cassette containing EGFP cDNA and GDNF cDNA under control of the bi-directional minimal CMV promoter (Figure 4b ).
In order to block the leakiness, we stably expressed the tetracycline-controlled transcriptional silencer (tTS) in Tet-on clones. tTS is a fusion of the tet repressor protein (TetR) and the KRAB-AB domain of the Kid-1 protein. 16 In the absence of doxycyclin, tTS binds to the tetO sequence in the TRE region, thereby preventing gene expression. The addition of doxycyclin switches the system from one that is actively repressed to one that is induced. As illustrated in Figure 4c , this was indeed the case for clone 14 (and clone 9; data not shown). The basal expression for the majority of the cells was completely blocked when tTS was stably expressed in the cells, while the doxycyclin-induced expression remained virtually unchanged.
To evaluate if the Tet-on system could direct stable in vivo gene expression in transplanted cells, two clones, HiB5-z9 and HiB5-z10 were transplanted to the rat striatum. In control animals receiving transplants but no doxycyclin treatment (n = 6) only single EGFP+ cells were detected at the transplantation site at day 14 after implantation similarly to what was observed after transplantation of constitutively expressing clones. No increase in the number or intensity of EGFP+ cells was found in animals in the doxycyclin treated group.
A lentiviral vector system for regulated expression Lentiviral vector (LV) mediated in vivo transfer of transgenes directly to brain tissue has been shown to mediate sustained expression of the transgene. 10 To take advantage of this quality of the lentiviral vector, the Tet-on elements were incorporated in two LV transfer vectors, pHR'-rtTA and pHR'-GTE ( Figure 5a ). As in the plasmid construct, rtTA is constitutively expressed from a CMV promoter in the pHR' constructs.
Virus vector stocks of all constructs were generated, and the ability of the LV incorporated Tet-on system to regulate co-expression of GDNF and EGFP was investigated in HiB5 cells. HiB5 cells transduced with the twovector system at a 1:1 ratio generated a sub-population of cells with high expression level upon doxycyclin addition (Figure 5b ). The polyclonal culture was enriched for cells 
When tTS transrepressor is constitutively expressed in a subclone of the z14 clone basal expression is blocked in the majority of cells and comparable to non-transfected parental HiB5 cells (dashed line).
with strong fluorescence and single clones were isolated. Most of the isolated clones lost their transgene expression over time; however, a number of clones did show stable transgene expression after prolonged growth. All these clones showed a somewhat similar expression patterneg low basal expression, around 100-fold inducibility and almost identical maximum expression levels as exemplified by clones 1, 2, 5 and 7 ( Figure 5c ). To determine if the uniform expression patterns were related to transgene copy number, Southern analysis of clones 1, 2, 5 and 7 was carried out. Southern analysis revealed that transgene copy number varied (between 1 and 3) among the clones and, notably, the integration event had occurred at different chromosomal sites in each clone (data not shown). Clone 7, harboring a single transgene copy, showed lowest expression levels (Figure 5c) .
A doxycyclin dose-response experiment revealed a very close correlation between GDNF and EGFP expression as observed with the one-plasmid clones (Figure 5d ). However, compared with plasmid clones, induction of expression was more tightly regulated Gene Therapy (Figures 3c and 5d ). Expression could be turned on and off with kinetics similar to plasmid clones (data not shown) and, finally, while maximum expression levels of GDNF were similar to those obtained in plasmid clones, eg in the range 4 ng/10 5 cells/18 h, the basal, noninduced expression levels were minimal. The low, basal expression could be completely prevented by stable expressing the tTS transrepressor, as illustrated for clone 5 (Figure 5e ). Interestingly, addition of doxycyclin to culture medium could not completely unblock all cells from the tTS-mediated suppression, a small fraction of cells did not reach the maximum expression level while fully induced by doxycyclin, as observed in the parental cells without the tTS (Figure 5e ).
Transplantation of LV HiB5 clones
To study the stability of in vivo transgene expression from the stable HiB5 clones generated by transduction with Tet-on LV vector constructs, clones were transplanted to the rat striatum. Six doxycyclin pre-induced clones were each transplanted unilaterally to three rats (nine rats in total) that were pre-treated with doxycyclin for 3 days and received doxycyclin daily over the course of the experiment. At day 10 after transplantation, single EGFP+ cells could be observed close to the needle tract, consistent with previous observations after transplantation of clones generated by plasmid DNA transfection. Both undifferentiated and differentiated (mostly astroglial) cell morphologies were seen among the EGFP+ cells (see Figure 2g-i) . In accordance with these observations GDNF staining revealed very weak signals close to the needle tract (data not shown).
Discussion
Ex vivo gene transfer is an attractive means of therapeutic gene delivery to the CNS, but has so far been hampered by lack of transgene expression stability. The goal of the present study was to evaluate the capability of different expression systems incorporated in both plasmid-and lentiviral-based vectors to direct stable ex vivo transgene expression.
For constitutive expression, we employed the human UbC promoter based on previous studies that established the strength and versatility of UbC. 5, 6 Indeed, the present data demonstrated high level and long-term in vitro stability of UbC-directed transgene expression in CHO, as well as in HiB5 cells comparable to the CMV promoter. GDNF expressing HiB5 cells continuously released high amounts of biologically active GDNF that in a subsequent study was shown to be sufficient to promote survival of dopaminergic neurons in co-culture with porcine ventral mesencephalic tissue. 17 To compare constitutive transgene expression to regulated expression for in vitro and in vivo use, we employed the tetracycline (Tet) inducible expression system. 7 The Tet system has gained widespread use for transgene regulation in gene transfer approaches (reviewed in Ref. 18 ). In the Tet-on system a transactivating factor will bind to the operator sequence in the presence of tetracycline (or its derivative doxycyclin) to activate transcription. 19 We combined the Tet-on elements in a single vector and demonstrated time-and doxycyclin dose-dependent in vitro inducibility and a close correlation between EGFP and GDNF expression from the bi-directional promoter.
All plasmid Tet-on clones showed to varying extents residual basal activity in the non-induced state. Leakiness of the Tet system is an often-reported phenomenon that could limit its use in certain applications. 12, 19, 20 Several factors could contribute to the residual activity: intrinsic activity of the minimal promoter, number of copies integrated, 21 low affinity binding of rtTA to the response element despite the absence of doxycyclin, or, enhancer elements in proximity to the integration site promoting the activity of the minimal promoter contained in the TRE. 7 Regarding the last point, Bujard et al 22 and Yin et al, 20 have recommended not co-transfecting the (CMVϪ) expression unit of the transactivator and the response element since the minimal promoter might function as an enhancer trap amenable to influence by a close-by integrated CMV enhancer/promoter. We specifically investigated this assumption by generating mutant versions of the pJJ/GTE vector and assessing expression in polyclonal cultures. No difference in background expression between native and mutant constructs was observed when the CMV promoter was deleted (pJJ/GTE dCR ) or transactivator translation abolished (pJJ/GTE STOP ). Moreover, basal activity of the TRE element was demonstrated in transient transfection experiment, though it cannot be ruled out that some of the transcriptional activity originates from integrated copies of the transgene. Thus, the data indicate that basal expression in the plasmid Tet-on clones is not influenced by cis-acting elements in the nearby CMV promoter or by low affinity binding of rtTA to the minimal CMV promoter, but rather originates from intrinsic activity of the minimal promoter itself. The difference in basal expression levels and regulatability among clones is likely related to a difference in transgene copy number and, importantly, the effect of integrating the transcriptional unit proximal or distant to endogenous enhancers or other cis-acting elements that influence the activity of the minimal promoter.
In contrast to the variability in expression levels of plasmid clones, inducible LV clones showed very similar expression patterns: transgene expression was stable for prolonged periods in vitro, basal levels were low, there was a very tight doxycyclin dose dependency and expression could be induced~100 fold and repeatedly be turned on and off. The literature describe different means to obtain inducible clones with reduced basal activity, including substituting the minimal CMV promoter with a modified mouse mammary tumor virus promoter, 23 flanking the inducible promoter with insulator elements 24 or co-transfecting a transcriptional silencer/TetR (tTS) fusion protein that binds TRE in absence of doxycyclin and minimize basal expression. 16 In the present study, we demonstrated that when tTS was stably expressed in inducible clones the majority of cells showed virtually no non-induced basal expression levels. While basal expression could be blocked by stable expressing tTS, in
Gene Therapy the case of HiB5-LV clone 5 to a level indistinguishable from non-transduced cells, not all cells could be relieved from the tTS-mediated suppressing effect. A fraction of the cells did not reach the maximum induced expression level characteristic of the parental clone. Nevertheless, it demonstrates that non-induced expression can be almost completely blocked, providing considerable advantage for clinical use. From a safety point of view, it has important implications since the long-term effects of constitutively expressing neurotrophic factors ectopically in the human brain essentially are unknown and a medical product needs a switch to turn off expression. From a pharmacological perspective, such a tight control of gene expression is desirable in order to control transgene expression to appropriate therapeutic levels.
The present in vitro data show that precise administration of doxycyclin can fine-tune expression in vitro to meet stringent demands of expression levels of a given transgene from the single plasmid vector or from the two-vector LV system. In that respect, fluorescence is shown to be a reliable marker of expression of the second, co-expressed gene. Moreover, comparing the activity of the fully induced minimal CMV promoter with constitutive promoters shows that the activity is comparable to the CMV and UbC promoters. Expression of GDNF from all vector systems was in the range 2-4 ng GDNF/10 5 cells/h which is comparable to retroviral transduced HiB5 cells expressing NGF. 25 In conclusion the in vitro data suggest that HiB5 cells engineered to express GDNF from constitutive or inducible promoters in a plasmid or lentiviral vector system could be a valuable tool in ex vivo gene therapy strategies in the PD rat model. Grafted HiB5 cells engineered to express the reporter gene in vivo under the constitutive (CMV and UbC) or inducible plasmid vector promoter failed to sustain expression of the transgene. This could not be ascribed to clonal artifacts, since all clones tested displayed a similar pattern of down-regulation. Though increased levels of GDNF was released at day 3 after grafting, it was not sufficient to accomplish significant protection of dopaminergic neurons in the 6-OHDA rat model. The observed down-regulation is in line with previous ex vivo studies. These studies have shown gradual decline of transgene expression from retroviral vectors in cerebral endothelial cells, 3 primary astrocytes 2, 4 or fibroblast 26 despite longterm graft survival. The present data show that plasmid vector-mediated gene expression, similar to retroviral vectors, is down-regulated in vivo. Moreover, the data confirm that down-regulation is a general phenomenon that exists independently of cell type, transgene or promoter in use. Transgene down-regulation was evident in most cells of LV-Tet clones at day 10. Since LV vectors direct sustained in vivo transgene expression in the rat brain, 10, 27 and LV vector-mediated gene transfer in other cell transplantation paradigms can sustain gene expression in vivo, for instance hematopoietic stem cells 28 or islet grafts, 29 the observed transgene silencing in HiB5 ex vivo gene transfer to the CNS suggests that the responsible mechanisms for transgene down-regulation are not directly related to the transcriptional unit. More likely, down-regulation is a consequence of the grafted HiB5 cells switching from a proliferative state to a differentiated state in which the gene expression profile is changed and the overall transcriptional activity is reduced. Apparently expression was stable in a low, but readily detectable number of cells and it cannot be ruled out that expression could continue in single cells for a prolonged time. For instance, it has recently been shown, that ex vivo gene transfer of LV vector transduced polyclonal HiB5 cells to neonatal rats could promote sustained transgene expression (8 weeks), though expression levels were considerably reduced in most cells.
14 The same study also showed that the time aspect of downregulation apparently is cell type-related, since in vivo transgene expression was found to vary between cells of different type transduced with the same LV reporter construct and grafted to the rat brain.
The actual mechanism associated with transgene silencing are not fully understood, however, in vitro and in vivo studies have shown that de novo methylation of transcriptionally regulating sequences or coding sequences, 30 ,31 acetylation of histones, 32 position effects, transgene copy number 21 and extrusion of introduced transgenes 33 are contributing factors. Including so-called insulator sequences to flank the transcriptional unit may be a promising strategy to shield the transgene from cisacting elements 34 and increase the possibility that an integrated transgene will be expressed. 35 Though different approaches were used to select single clones generated by transfection or transduction, and a direct comparison of virus-and plasmid-mediated expression and regulation is not straightforward, it was nevertheless interesting to find that all isolated HiB5-LV Tet clones, in contrast to HiB5 plasmid Tet-on clones, had very uniform expression patterns with almost identical basal and induced expression levels. We have recently employed the cHS4 insulator elements 36 that successfully sustained in vivo expression of a reporter plasmid in HiB5 cells (non-published data). Interestingly, in vitro expression patterns of these clones closely resemble expression patterns of the HiB5-LV Tet clones. In the present study, we observed that similar expression patterns in four HiB5-LV Tet clones were integration site-independent. This apparent lack of preferential integration of an LV vector in cultured cells is supported by a recent report. 37 This raises the possibility that elements in the LV vector serve to protect the transcriptional unit from position effects through an as yet undescribed insulating activity in the virus vector similar to cHS4. The observed long-term in vivo expression of LV vectors 10 might therefore partly be mediated through an insulating effect of the vector that serves to prohibit access of negative factors. However, though the expression level is not necessarily proportionally correlated to the number of integrated transgenes, the observation that the expression levels in HiB5-LV Tet clones to some extent were copy number independent do not favor such an insulator existence.
In conclusion, the present study has demonstrated that the often encountered phenomenon of transgene silencing in transplanted retrovirally engineered cells also apply to cells engineered with plasmids that express transgenes from strong constitutive or inducible promoters. Moreover, LV vector ex vivo gene transfer did not solve the silencing problem, but the attractive features of LV vectors give some hope for the future. The present data clearly emphasize that more knowledge concerning the chromatin and its dynamics during the differentiation process of the grafted cells is needed. This reinforces the view that alternative vector strategies for ex vivo gene transfer are required for this approach to have clinical relevance in diseases characterized by a chronic course.
Materials and methods
Vector constructs
Constitutive vectors: For efficient transfection and expression the human UbC promoter was cloned into a modified version (pCMVz) of pcDNA3.1/Zeo (Invitrogen, San Diego, CA, USA), by replacing the CMV promoter, generating pUbi1z. 6 PCR-amplified human GDNF cDNA was cloned in the HindIII/NotI site of pUbi1z or pCMVz. Inserting the green fluorescence reporter gene, EGFP, cDNA in the EcoRI/XhoI site of pUbi1z or pCMVz, generated pUbi1z-EGFP and pCMVz-EGFP, respectively (Figure 1a) .
For constitutive expression of the transrepressor, tTS, pUbi1h was made by replacing the zeocin cDNA with hygromycin cDNA in pUbi1z as a BspLUII/MscI fragment. The transrepressor, tTS was PCR amplified from pTet-tTS (Clontech, Palo Alto, CA, USA) and ligated in the HindIII/XhoI site of pUbi1h.
Inducible vector:
To create a one-vector inducible construct pJJ/GDNF/TRE/EGFP (pJJ/GTE) a number of subclonings steps were performed. pJJ was generated as follows: pTet-On (Clontech) was modified to eliminate the EcoRI site at position 767 and the BamHI site at position 1792, by partial digesting with the appropriate enzymes. From this plasmid a fragment containing the CMV promoter and the transactivator (rtTA) was PCR amplified (1904 bp) with primers containing 5' recognition sites for BglII and NheI, respectively. In parallel an EcoRI fragment from the bi-directional Tet vector pBI (Clontech) containing the response element (TRE) and minimal promoter was ligated in the EcoRI site of pCMVz generating pCMVz-TRE. The pTet-On 1904 bp BglII/NheI fragment was ligated in the BglII/NheI site of pCMVz-TRE generating the plasmid pJJ.
In the next step, an XhoI/Bsp120I EGFP fragment from pLXSNEGFP (Clontech) and a pwo polished GDNF HindIII/NotI fragment from pUbi1-GDNF was ligated in the SalI/NotI site and the EcoRV site, respectively, of the bi-directional Tet vector, pBI (Clontech) thus generating pBI/EGFP/GDNF.
In the final step, an EcoRI fragment containing the TRE element and the minimal promoter was cut out of pJJ. The vector was religated and linearized with NheI. From pBI-EGFP-GDNF an XbaI fragment containing the EGFP/TRE/GDNF cassette was cut out and ligated in the NheI site of pJJ generating the final vector pJJ/GDNF/TRE/EGFP (pJJ/GTE; Figure 3a) .
In this construct GDNF and rtTA shares the 'bi-directional' SV40 polyadenylation signal. If properly functioning, constitutively expressed rtTA will bind to the TRE element in the presence of tetracycline, or one of its derivatives, doxycyclin, thus directing co-expression of GDNF and EGFP.
pJJ/GTE mutants: To introduce a translational stop in the rtTA cDNA, pJJ/GTE was cut with BsrDI, pwo polished and religated. This generated a 2-bp deletion, thus introducing a premature stop signal at nucleotide 330. This con-struct was designated pJJ/GTE STOP . The CMV promoter driving constitutive expression of rtTA, and 5' 288 bases of rtTA, was deleted by cutting out a BspHI/BsrDI fragment from pJJ/GTE. This construct was designated pJJ/GTE dCR . The native and mutated versions of the pJJ/GTE vector system were transfected (double transfection for all constructs) to HiB5 cells generating pools of zeocin-resistant clones. Transgene expression in polyclonal cultures was induced over 7 days by adding 1 g/ml dox to cell media. Levels of fluorescence were determined by FACS analysis and compared.
Lentivirus (LV) vector constructs:
To generate pHR'-GDNF/TRE/EGFP (pHR'-GTE), the GDNF/TRE/EGFP cassette from pJJ-GTE was PCR amplified with primers containing 5' recognition sites for ClaI and SalI, respectively, and ligated in ClaI/XhoI site of pHR'CMV-EGFP-WPRE. By this means, the CMV promoter and EGFP cDNA in pHR'CMV-EGFP-WPRE was eliminated.
To express the reverse transactivator, rtTA was PCR amplified from pJJ/GTE with primers containing 5' recognition sites for BamHI and XhoI, respectively and ligated in pHR'CMV-WPRE. This generates pHR'-rtTA.
Generation of cell lines
The HiB5 cell line is a multipotent conditionally immortalized stem cell line, derived from the E16 rat hippocampus. 13 Cells were expanded at the permissive temperature for the immortalizing oncogene (+33°C, tsA58/U19 mutant allele of the SV40 large T-antigen) in Dulbecco's modified Eagle's medium with Glutamax (Gibco, Life Technologies, Denmark) supplemented with 10% heatinactivated fetal bovine serum and 5 g/ml gentamycin. Plasmid transfections in HiB5 cells or CHO cells were done using the Lipo Plus transfection system in accordance with the manufacturer's (Life Technologies) recommendations. Two g vector DNA was transfected to 5 × 10 5 cells, and the following day cells were split and grown in the presence of the relevant antibiotics (100 g/ml zeocin; 120 g/ml hygromycin).
Production of lentiviral vector
Production of lentiviral vectors was performed as described previously. 38 Briefly, the transfer constructs and the helper plasmids pCMV⌬R8.91 and pMDG were co-transfected into 293T cells. Virions released into the media were collected at 48 and 72 h after transfection and concentrated by centrifugation at 141 000 g for 1.5 h. A RNA slotblot technique 39 was subsequently used to determine viral particle titer. The titer of the two LV constructs pHR'-rtTA and pHR'-GTE was determined to be 4.8 × 10 10 and 8.0 × 10 9 particles/l, respectively.
Southern blotting
Chromosomal DNA was extracted from cells according to the manufacturer's (Qiagen) recommendations. Southern blot was performed in accordance with protocol. 40 Briefly, 15 g chromosomal DNA was digested with BsrGI, run on a 0.8% agarose gel at low voltage overnight and blotted to a nylon membrane. Hybridization analysis was carried out with a PCR-labelled EGFP probe. After a high stringency wash, the blot was exposed to a phosphor imaging plate (Fujifilm, Denmark).
Gene Therapy GDNF ELISA GDNF was measured in clones or from tissue using the GDNF E max immunoassay system (Promega, Madison, WI, USA). A total of 72 zeocin-selected HiB5 clones were isolated, expanded and monitored for GDNF expression. In all clones GDNF was expressed to a varying extent ranging from 0.1 to 2.5 ng/h/10 5 cells and the two highest producers were picked for transplantation experiments. GDNF levels in brain tissue were measured 3 and 21 days after implantation of HiB5-GDNF or control HiB5. Two coronal slices at the level of the striatum (3 mm) and substantia nigra (2 mm) were cut and the head of the caudate-putamen, and the substantia nigra was dissected out and stored at -80°C until assayed. The tissue was sonicated in a homogenization buffer (150 mM NaCl, 50 mM TRIS, pH 7.4, 1% Triton X-100, 1.7 g/ml phenylmethylsulfonyl fluoride, 1.0 g/ml leupeptin, 10 g/ml aprotinin and 1 g/ml pepstatin) at 30 mg/ml. The supernatant was assayed according to the supplier's recommendation.
Flow cytometry analysis
Trypsinized cells were resuspended in 2 ml culture medium. Fluorescence activated cell sorter (FACS) analysis for cellular EGFP was performed by FACScan analysis (Becton Dickinson) with the CellQuest program.
Surgical procedures
All animal experiments were performed according to the guidelines set by the Danish Committee for Use of Laboratory Animals and the Ethical committee at Lund University. Sixty-two young female Sprague-Dawley rats (B&K Universal, Stockholm, Sweden and Møllegaard, Denmark) were housed in a 12 h light:dark cycle with free access to water and food. In the experiments with cell lines carrying the tetracycline-inducible promoter, doxycyclin was administered through the drinking water (2 mg/ml + 5% w/v sucrose) or p.o. injection (20 mg/kg/day) from 3 days before transplantation until death.
For all animal experiments, halothane anesthesia was used and cells were implanted using a Kopf stereotactic instrument. All transplantations in intact animals for morphology or GDNF-ELISA were made bilaterally into the striatum at the following coordinates: AP +1.0 mm, ML ±3.0 mm from bregma and DV -5.0 from the dura. The incisor bar was set at 0.0 mm. A total of 200 000 cells in 2 l were implanted on each side. In the 6-OHDA lesion experiment, cells were implanted over the substantia nigra at AP -5.2 mm, ML Ϫ2.0 mm from bregma and DV -6.2 from the dura. The incisor bar was set at -2.3 mm. In the same session, 0.2 l of the retrograde tracer fluorogold (2% w/v solution in saline; Fluorochrome, Englewood, CO, USA) were injected bilaterally into the striatum at AP +1.0 mm, ML Ϫ3.0 mm from bregma and DV -5.0 from the dura. One week after transplantation/retrograde labelling a 6-OHDA lesion was performed as described by Rosenblad et al. 41 At death, animals for morphological evaluation were deeply anesthetized by sodium pentobarbital and transcardially perfused with ice-cold saline for 1 min followed by 200 ml 4% paraformaldehyde in 0.1 M phosphate buffer. The brains were dissected out and post fixed in the same fixative for 4 h and then immersed in phos-
